Searchable abstracts of presentations at key conferences in endocrinology
Previous issue | Volume 56 | ECE2018 | Next issue

20th European Congress of Endocrinology

Barcelona, Spain
19 May 2018 - 22 May 2018

Card image cap
ECE 2018, 19 - 22 May 2018; Barcelona, Spain

Guided Posters

Adrenal medulla and NETs

ea0056gp42 | Adrenal medulla and NETs | ECE2018

Pituitary adenoma and pheochromocytoma/paraganglioma: a multicausal association of tumors

Guerrero Fernando , Fajardo Carmen , Vela Elena Torres , Gimenez-Palop Olga , Gil Arturo Lisbona , Martin Tomas , Gonzalez Natividad , Diez Juan Jose , Iglesias Pedro , Villabona Carles

Background: Pituitary adenomas (PA) and pheochromocytomas/paragangliomas (PCC/PGL) are the main components of MEN1 and MEN2, respectively. Although the presence of both tumors (3P association, 3PAs) in the same patient could be as a result of coincidence, at least in some cases, a common pathogenic mechanism has been involved. Recently has been confirmed that germline mutations in genes coding succinate dehydrogenase (SDH) play a role in pituitary tumorigenesis. Furthermore, M...

ea0056gp43 | Adrenal medulla and NETs | ECE2018

Ex vivo metabolomic profiling in phaeochromocytoma, paraganglioma and GIST tumours: lessons learned

Casey Ruth , Madhu Basetti , Challis Benjamen G , Clark Graeme R , ten Hoopen Rogier , Giger Olivier , Marker Alison , Bulusu Venkata R , McLean Mary , Gallagher Ferdia A , Maher Eamonn R

Recent discoveries in mutations in TCA cycle enzymes; succinate dehydrogenase (SDH), fumarate hydratase (FH), iso-citrate dehydrogenase (IDH) and malate dehydrogenase MDH2, have reinforced the link between mitochondrial dysfunction and cancer1. Phaeochromocytoma and paraganglioma (PPGL) are now recognised to be the most heritable tumour, with 40%1 having a genetic defect. Mutations in the SDH genes are the most frequently implicated genetic abnor...

ea0056gp44 | Adrenal medulla and NETs | ECE2018

Mortality in patients with Pheochromocytoma: a population-based study 1977–2016

Ebbehoj Andreas Ladefoged , Sondergaard Esben , Jacobsen Sarah Forslund , Trolle Christian , Robaczyk Maciej Grzegorz , Rasmussen AEse Krogh , Feldt-Rasmussen Ulla , Thomsen Reimar Wernich , Stochholm Kirstine , Poulsen Per Logstrup

Background: Pheochromocytomas and catecholamine-secreting paragangliomas (PPGL) are rare catecholamine-producing tumors. Due to the rarity, limited data on prognosis exists and data are mainly from tertiary centers with potential referral bias. Here, we present population-based mortality data over an observation period of 40 years.Materials and methods: We identified a cohort of 198 PPGL patients diagnosed 1 January 1977 to 31 December 2016 in North and ...

ea0056gp45 | Adrenal medulla and NETs | ECE2018

The 10 Hounsfield Units cut-off value on unenhanced CT imaging is highly sensitive to diagnose pheochromocytoma: a multicenter study

Buitenwerf E , Korteweg T , Haag MSC , Feelders RA , Timmers HJLM , Canu L , Haak HR , Bisschop PHLT , Eekhoff EMW , Corssmit EPM , Dullaart RPF , Links TP , Kerstens MN

Introduction: A substantial proportion of pheochromocytomas (PCC) are detected during the work-up of an adrenal incidentaloma. Recently it has been suggested that in case of an adrenal incidentaloma with an unenhanced attenuation value <10 Hounsfield Units (HU) on CT imaging biochemical testing to rule out PCC is unnecessary. We aimed to determine the sensitivity of the 10 HU cut-off value to detect pheochromocytoma.Methods: Retrospective multicenter...

ea0056gp46 | Adrenal medulla and NETs | ECE2018

Comparative study between incidental and symptomatic pheochromocytoma

Santacruz Elisa , Ortiz-Flores Andres , Diez Juan Jose , Pian Hector , Marengo Agustina P , Garcia-Sancho Paula , Peiro Inmaculada , Villabona Carles , Iglesias Pedro

Introduction: The widespread use of abdominal computed tomography and magnetic resonance imaging has led to a rise in the diagnosis of incidental adrenal lesions, some of them are pheochromocytomas (Pheo).Objective: To investigate the differences between incidental (IPheo) and symptomatic Pheo (SPheo).Methods: A multicenter retrospective study on clinical and pathological characteristics, treatment and outcome in patients with Pheo...

ea0056gp47 | Adrenal medulla and NETs | ECE2018

Identifying active steroids, steroid receptors and pathways in the normal breast and their potential relationship to obesity and cancer development

McNamara Keely , Kanai Ayako , Moon Ju-Yeon , Choi Man-Ho , Sasano Hironobu , Brown Kristy

Introduction: While a great degree of focus has recently been placed on identifying novel steroidogenic pathways that are active in cancer development (e.g. Androgen metabolism and Androgen Receptor (AR) Signalling, Glucocorticoid Metabolism and Glucocorticoid receptor (GR) signalling) very few studies have examined these pathways in normal breast samples taken under non-pathological conditions. Furthermore, very few studies have examined the steroid levels in non-pathological...

ea0056gp48 | Adrenal medulla and NETs | ECE2018

In vitro studies reveal a potential therapeutic role of the combination of biguanides and statins for the treatment of prostate cancer

Herrero-Aguayo Vicente , Jimenez-Vacas Juan M , Gomez-Gomez Enrique , Leon-Gonzalez Antonio J , Saez-Martinez Prudencio , Requena-Tapia Maria J , Gahete Manuel D , Castano Justo P , Luque Raul M

Prostate cancer (PCa) is the most common tumor pathology in men worldwide. The medical treatments currently used as first-line therapy after surgery are anti-androgens like abiraterone or enzalutamide, which, unfortunately, fail to stop the disease in a high percentage of cases, resulting in progression towards aggressive castration-resistant PCa. Therefore, new therapeutic tools to manage PCa are urgently needed. Biguanides and statins, two types of drugs commonly used in met...

ea0056gp49 | Adrenal medulla and NETs | ECE2018

Targeted destruction of FSHR-positive cancer cells by a lytic Phor21-FSHb conjugate

Chrusciel Marcin , Stelmaszewska Joanna , Doroszko Milena , Ponikwicka-Tyszko Donata , Toppari Jorma , Wolczynski Slawomir , Ziecik Adam , Huhtaniemi Ilpo , Rahman Nafis

Expression of the follicle-stimulating hormone receptor (FSHR) has been shown in gonads, gonadal tumors, and in endothelial tumor vessel cells of various cancers. We investigated the specificity and cytotoxicity of a fusion lytic peptide Phor21, conjugated to different FSHβ-chain fragments to ablate FSHR expressing cancer cells in vitro and in vivo. Cytotoxicity of 12 different Phor21-FSHβ conjugates was tested in HEK-293 cells, stably transfected w...

ea0056gp50 | Adrenal medulla and NETs | ECE2018

Abstract withdrawn....

ea0056gp51 | Adrenal medulla and NETs | ECE2018

Evolution of mesenteric metastasis in small intestinal neuroendocrine tumours (SI-NETs)

Blazevic Anela , Zandee Wouter T , Hofland Johannes , Franssen Gaston JH , van Velthuysen Marie-Louise F , Brabander Tessa , Feelders Richard A , de Herder Wouter W

Background: A metastatic mesenteric mass is a hallmark of small intestinal neuroendocrine tumours (SI-NETs). However, little is known about the evolution of a SI-NET-associated mesenteric mass over time.Methods: Retrospectively, 530 patients with proven SI-NET and ≥2 available CT-scans were assessed for clinical characteristics at diagnosis and the presence and growth of a mesenteric mass on every consecutive CT-scan until end of follow-up or resec...

ea0056gp52 | Adrenal medulla and NETs | ECE2018

Epidemiology and clinical significance of clinical hormonal syndromes in patients with neuroendocrine tumors

Popovic Bojana , Macut Djuro , Antic Ivana Bozic , Bogavac Tamara , Ilic Dusan , Isailovic Tatjana , Elezovic Valentina , Ognjanovic Sanja , Damjanovic Svetozar

Introduction: Hormonal syndromes are significant cause of morbidity in patients with neuroendocrine tumors (NET), requiring special treatment, rarely completely efficient. Effect on mortality is also presumed. Our aim was to investigate epidemiological characteristics of NET with hormonal production in our group of patients.Patients and methods: We analyzed 822 patients with NET of various primary tumor sites, treated at our department during period of 2...